| 000 | 01479 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250517182009.0 | ||
| 264 | 0 | _c20190114 | |
| 008 | 201901s 0 0 eng d | ||
| 022 | _a1096-7206 | ||
| 024 | 7 |
_a10.1016/j.ymgme.2017.10.001 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMac Lochlainn, Dylan J | |
| 245 | 0 | 0 |
_aThe utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa. _h[electronic resource] |
| 260 |
_bMolecular genetics and metabolism _c02 2018 |
||
| 300 |
_a154-158 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aEnzyme Replacement Therapy |
| 650 | 0 | 4 |
_aFabry Disease _xenzymology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoenzymes _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 |
_aRecombinant Proteins _xadministration & dosage |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 |
_aalpha-Galactosidase _xadministration & dosage |
| 700 | 1 | _aMcKechnie, Douglas G J | |
| 700 | 1 | _aMehta, Atul B | |
| 700 | 1 | _aHughes, Derralynn A | |
| 773 | 0 |
_tMolecular genetics and metabolism _gvol. 123 _gno. 2 _gp. 154-158 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ymgme.2017.10.001 _zAvailable from publisher's website |
| 999 |
_c27707866 _d27707866 |
||